EDIT logo

EDIT Editas Medicine, Inc.

NASDAQ · Biotechnology · Healthcare

$2.22
-0.16 (-6.89%)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The …

Market Cap: $342.00Mwww.editasmedicine.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
50
1 mentions
—
60d
53
4 mentions
—
90d
51
8 mentions
—
news: 8

Analyst Ratings

26 analysts
Buyconsensus
Strong Buy 0Buy 16Hold 8Sell 2Strong Sell 0
Avg price target$5.5+148.2%
Low $5Median $5.5High $6
Current Consensus

Revenue

$10.37M+1054.23%
$42.0K$20.98M$41.91M$62.84M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.98
$-2.09–$-1.89
7 analysts
FY2026
$-0.74
$-0.92–$-0.60
6 analysts
FY2027
$-0.69
$-0.99–$-0.56
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Gilmore O'Neill
Sector
Healthcare
Industry
Biotechnology
Employees
87
Beta
2.08
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-9.36
www.editasmedicine.com